

1

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

3

Guideline scope

4

Diagnostic services: organisation and delivery

6

Topic

7

8 The Department of Health in England and NHS England has asked NICE to
9 develop service guidance on the organisation and delivery of diagnostic
10 services.

11 For more information about why this guideline is being developed, and how
12 the guideline will fit into current practice, see the [context](#) section.

Who the guideline is for

13

- 14 • Healthcare professionals in primary, secondary and tertiary care who
15 access, use or refer for diagnostics.
- 16 • Commissioners of diagnostic services.
- 17 • Secondary and tertiary care providers of diagnostic services.
- 18 • All settings in which NHS care is provided or commissioned.

19 It may also be relevant for:

19

- 20 • Private sector or voluntary organisations (for example community trusts)
21 commissioned to provide services for the NHS.
- 22 • People using services, families and carers and the public.

23 NICE guidelines cover health and care in England. Decisions on how they
24 apply in other UK countries are made by ministers in the [Welsh Government](#),
25 [Scottish Government](#), and [Northern Ireland Executive](#).

25

26 ***Equality considerations***

27 NICE has carried out [an equality impact assessment](#) during scoping. The
28 assessment:

- 29 • lists equality issues identified, and how they have been addressed
- 30 • explains why any groups are excluded from the scope.

31 The guideline will look at inequalities relating to access to diagnostic service
32 provision, for example for people living in remote geographical locations,
33 people with physical and mental disabilities, non-English speaking populations
34 and people from disadvantaged socioeconomic backgrounds.

35 **1 What the guideline is about**

36 A diagnostic service is a service that undertakes or provides diagnostic tests.
37 These are procedures or measurements performed to confirm, or determine
38 the presence or absence of, disease or abnormality or severity or progression
39 of disease. Diagnostic tests are usually done after a person reports
40 symptoms, or they can be based on the results of other medical tests, or
41 carried out for people with risk factors for specific conditions. Such tests fall
42 under the disciplines of imaging, pathology (including genetics, genomics and
43 molecular testing), endoscopy and physiology.

44 **1.1 Who is the focus?**

45 **Groups that will be covered**

- 46 • People needing diagnostic tests.
- 47 • Staff who refer for, carry out, receive and/or interpret the results of
48 diagnostic tests.
- 49 • No specific subgroups of people have been identified as needing specific
50 consideration.

51 **1.2 Settings**

52 **Settings that will be covered**

- 53 • All settings in which NHS care is commissioned or provided including:

- 54 – primary care
- 55 – secondary care
- 56 – tertiary care
- 57 – the community (including in people’s homes).

58 **1.3 *Activities, services or aspects of care***

59 **CommunicationbKey areas that will be covered**

- 60 1 How services are delivered.
- 61 2 Where services are delivered.
- 62 3 Access to, and communication between services.
- 63 4 Information and support needs of people using services, their families
- 64 and carers.

65 **Areas that will not be covered**

- 66 1 Which test to use to diagnose clinical conditions.
- 67 2 Subsequent changes in management following results of diagnostic
- 68 tests.
- 69 3 Which screening services should be provided.
- 70 4 History taking or physical examination that is carried out in the course of
- 71 the clinical consultation.

72 **1.4 *Economic aspects***

73 We will take cost and efficiency as well as other economic aspects into
74 account when making recommendations. We will develop an economic plan
75 that states for each review question (or key area in the scope) whether
76 economic considerations are relevant, and if so whether this is an area that
77 should be prioritised for economic modelling and analysis. We will review the
78 economic evidence and carry out economic analyses, using an NHS and
79 personal social services (PSS) perspective, as appropriate.

80 The preferred unit of effectiveness is the quality-adjusted life year (QALY).
81 Further detail on the methods, including where NICE’s standard health
82 economic approaches may not apply, can be found in the [interim methods](#)

83 [guide for developing service guidance](#) and the [manual on developing NICE](#)
84 [guidelines](#).

85 **1.5 Key issues**

86 While writing this scope, we have identified the following key issues:

87 1 How services should be configured to improve i) cost efficiency, ii)
88 accuracy, and iii) access. Service configuration will cover:

89 1.1 Where services are delivered, (e.g. location for services including
90 centralisation, diagnostic and clinical adjacencies). The aspects to be
91 examined include:

92 1.1.1 Booking systems

93 1.1.2 Timeliness (including availability of services)

94 1.1.3 Decision support systems

95 1.1.4 Specialist advice

96 1.1.5 Multidisciplinary communication

97 1.1.6 Standardisation of communication

98 1.1.7 Models of reporting

99 1.1.8 Information and support needs of people using diagnostic
100 services, their families and carers.

101 Please see section 5 for example review questions.

102 **1.6 Main outcomes**

103 The main outcomes that will be considered when searching for and assessing
104 the evidence:

105 1 Use of healthcare resources (such as; costs of repeated testing, costs of
106 unnecessary tests, etc)

107 2 Cost and efficiency measures

- 108 3 Accuracy
109 4 Patient and carer views and satisfaction
110 5 Staff satisfaction among providers of diagnostic services.

111

112 **2 Links with other NICE guidance, NICE quality** 113 **standards, and NICE Pathways**

114 **2.1 NICE guidance**

115 **NICE guidance about the experience of people using NHS services**

116 NICE has produced the following guidance on the experience of people using
117 the NHS. This guideline will not include additional recommendations on these
118 topics unless there are specific issues related to diagnostic services:

- 119 • [Patient experience in adult NHS services](#) (2012) NICE guideline CG138
- 120 • [Service user experience in adult mental health](#) (2011) NICE guideline
121 CG136

122 **NICE guidance in development that is closely related to this guideline**

123 NICE is currently developing the following guidance that is closely related to
124 this guideline:


125 [Service delivery and organisation for acute medical emergencies](#). NICE
126 guideline. Publication expected November 2016.

127 **2.2 NICE Pathways**

128 [NICE Pathways](#) bring together all related NICE guidance and associated
129 products on a topic in an interactive topic-based flow chart.

130 When this guideline is published, the recommendations will be added to a new
131 NICE pathway. An outline of this pathway, based on the scope, is included
132 below. It will be adapted and more detail added as the recommendations are
133 written during guideline development.

Diagnostic services overview



134

135

136 **3 Context**

137 **3.1 Key facts and figures**

138 The demand for diagnostic services is increasing due to increased life
139 expectancy, previously unrecognised unmet need, undiagnosed populations,
140 newly introduced preventive strategies and advances in technology.

141 According to [NHS diagnostic waiting times and activity data](#) (NHS England,
142 May 2015), a total of 19 million 'key diagnostic tests' were undertaken in the

143 whole of 2014/15. This is a 5.9% increase from 2013/14. The above report
144 also shows that monthly activity (the number of diagnostic tests undertaken
145 during the month) increased over the 12 months prior to publication in March
146 2015, with an average monthly increase 0.7%.

147 The [NHS Atlas of Variation in Diagnostic Services](#) (November 2013) highlights
148 significant variation in the quality and provision of diagnostic services across
149 England. Unwarranted variation (that is, variation that is not explained by
150 genuine differences in clinical need) is a significant concern, but in many
151 cases is not currently understood. Unwarranted variation means that a
152 patient's ability to access diagnostic services, and their ultimate health
153 outcomes, could be affected by their postcode.

154 Waiting and reporting times are key issues for diagnostic services. The
155 timeliness of diagnostic services is one of the most significant aspects of
156 providing a quality service, but this must be considered alongside the quality
157 of the result, and the interpretation and reporting of results to the referring
158 clinician. The 2013/14 NHS Constitution pledges that patients should not be
159 required to wait 6 weeks or longer for a diagnostic test. This is part of the legal
160 right to treatment within 18 weeks of referral. NHS trusts face a financial
161 penalty for non-delivery of this standard. For some conditions such as
162 suspected cancer, there are additional waiting time targets such as the 'two
163 week pathway' (the waiting time from initial GP referral to being seen by a
164 specialist).

165 According to [NHS diagnostic waiting times and activity data](#), the total number
166 of patients waiting 6 weeks or longer from referral for one of 15 key diagnostic
167 tests to be undertaken was 13,000 (at the end of March 2015). This was 1.5%
168 of the total number of patients waiting at the end of the month. The estimated
169 average (median) time that a patient had been waiting for a diagnostic test
170 was 2.0 weeks at the end of March 2015. In the past 12 months (April 2014 to
171 March 2015) the total number of patients waiting for a diagnostic test has
172 continued to increase with an average monthly increase of 0.5%.

173 The move towards a 7-day NHS may have an impact on the provision of
174 diagnostic services, which underpin clinical decision-making. [Challenges and](#)
175 [improvements in diagnostic services across seven days](#) (NHS Improving
176 Quality) identifies variation in the availability of diagnostic services outside
177 normal working hours, which it is claimed can lead to delayed diagnosis,
178 poorer clinical outcomes and poorer patient experience.

179 **3.2 Current practice**

180 There is inconsistency in how diagnostics services are accessed. Some
181 services can be accessed directly from primary care and others only by a
182 secondary care referral. Access by secondary care referral can increase
183 patient waiting times because the patient has to first wait to be seen in the
184 secondary clinic, then wait for the diagnostics tests. Conversely, access from
185 primary care for complex modalities has the potential to increase unnecessary
186 referrals that would not be requested by a specialist secondary care clinician.

187 Some diagnostic tests are available at the point of care, whereas others
188 require the involvement of laboratories, highly trained staff and highly
189 specialised equipment. Factors such as the portability of equipment mean that
190 an increasing variety of tests can be provided in the community.

191 Some diagnostic services are provided locally, whereas others are centralised
192 in large hubs (or are in the process of being centralised). Some services are
193 co-located with the relevant clinical specialty, even though the service may
194 provide investigations for a broader range of specialties.

195 The number of tests passing through diagnostic services may be higher if they
196 are also used for population-based screening, and tests relating to the
197 ongoing management of chronic disease.

198 Some populations find it more difficult to access diagnostic services. These
199 include older people, people with multiple comorbidities or chronic conditions
200 who may need their condition to be monitored frequently, people who live in
201 remote geographical locations, people in travelling communities and others of
202 no fixed abode, such as homeless people.

203 Having diagnostic services in a variety of geographical locations may mean
204 that patients need to travel significant distances between sites. This could
205 result in costly transport, as well as time off work and school for families or
206 carers. Patients may also need to attend several different units for tests if
207 these are not co-located or provided as a 'one-stop shop'.

208 **3.3 Policy, legislation, regulation and commissioning**

209 **Policy**

210 The availability of safe effective services over 7 days a week is a current NHS
211 priority. Delivery of diagnostic services is central to any service
212 transformation. Ensuring high quality care for all and managing an increasing
213 demand for services requires innovative transformation in the delivery of
214 services as discussed in NHS England's framework for planning for people.

215 Relevant published policy documents include:

- 216 • [Equality for all – delivering safe care seven days a week – case studies](#)
217 [\(NHS Improvement Quality\)](#)
- 218 • [NHS services – open seven days a week: every day counts \(NHS](#)
219 [Improvement Quality\)](#)
- 220 • [NHS services, seven days a week forum](#)
- 221 • [Everyone counts: planning for patients 2014/15 to 2018/19](#) (NHS England)
- 222 • [Challenges and improvements in diagnostic services across seven days](#)
223 [\(NHS Improvement Quality\)](#).

224 The UK Strategy for Rare Diseases places great emphasis on the importance
225 of diagnosis: [https://www.gov.uk/government/publications/rare-diseases-](https://www.gov.uk/government/publications/rare-diseases-strategy)
226 [strategy](https://www.gov.uk/government/publications/rare-diseases-strategy)

227 The Genomic Laboratory Service re-design is currently ongoing:

228 <https://www.engage.england.nhs.uk/consultation/genomic-laboratories>

229 **Legislation, regulation and guidance**

230 Best practice guidance is produced by the medical Royal Colleges and other
231 professional bodies.

232 The National Screening Committee produces recommendations on screening
233 programmes across the UK.

234 State registration with the Health and Care Professions Council is a
235 requirement for some professions involved in providing diagnostic services,
236 for example biomedical scientists, clinical scientists and radiographers.

237 Accreditation schemes exist for most diagnostic disciplines (imaging,
238 pathology and genetic testing, endoscopy and physiological services) and
239 there are also internal and external quality assurance schemes in existence.

240 Regulations are in place for:

- 241 • Imaging - including [IR\(ME\)R 2000](#), [IR\(ME\) Amendment Regulations 2006](#),
242 [IR\(ME\) Amendment Regulations 2011](#), [The Ionising Radiations](#)
243 [Regulations 1999 \(IRR'99\)](#)
- 244 • Pathology and genetic testing - including [The Good Laboratory Practice](#)
245 [\(Codification Amendments Etc.\) Regulations 2004](#), [The Good Laboratory](#)
246 [Practice Regulations 1999](#), [The Good Laboratory Practice Regulations](#)
247 [1997](#), [UK Standards for Microbiology Investigations \(SMI\): quality and](#)
248 [consistency in clinical laboratories \(2014\)](#)

249 **Commissioning**

250 Commissioning of diagnostic services is recognised as a particular challenge,
251 particularly ensuring that the services delivered are of high quality, effective
252 and timely to support all clinical pathways. Clarity and harmonisation of
253 practice across the NHS is needed to address variation in practice and
254 diagnostic testing rates. Information has been produced by NHS improvement
255 with a view to aiding commissioners and service providers in meeting the
256 commissioning challenge:

- 257 • [Top tips to overcome the challenge of commissioning diagnostic services](#)
- 258 • [Directory of diagnostic services for commissioning organisations](#).

259 **4 Further information**

This is the final scope.

The guideline is expected to be published in November 2017.

You can follow progress of the [guideline](#).

Our website has information about how [NICE guidelines](#) are developed.

260

261 **5 Draft review questions**

262 The following questions have been drafted in relation to the key issues. These
263 will form the basis of more detailed review questions developed with the help
264 of the guideline committee to guide the systematic review of the literature. We
265 are aware that most of the key issues are strongly linked, and therefore some
266 of the questions may overlap between areas (such as where services are
267 delivered and communication between services).

268 1 What model of access to diagnostic tests improves outcomes?

269 2 What is the best arrangement of diagnostic services to most
270 efficiently take, analyse and report diagnostic tests?

271 3 Does co-location of diagnostic services improve outcomes?

272 4 Does co-location of diagnostic services with clinical/therapeutic
273 management services improve outcomes?

274 5 Do decision-support systems prior to referral improve outcomes?

275 6 What method of arranging appointments improves outcomes?

276 7 Does clinician access to specialist advice prior to referral and
277 following results improve outcomes?

278 8 What model of multi-disciplinary communication improves
279 outcomes?

280 9 Does standardisation of test requests and reporting improve
281 outcomes?

282 10 What models of reporting improve outcomes?

283 11 What information and support do people using diagnostic services
284 and their families and carers want (before the test and following reporting of
285 the results)?

286